South Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir, that research ...

The Senate is poised to vote this week on President Donald Trump's rescissions package requesting roughly $9.4 billion in ...

Global deaths from AIDS have dropped to their lowest levels in more than 30 years, but US funding cuts could soon reverse that progress.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...

This 2011 electron microscope image made available by the Centers for Disease Control shows HIV virions. On Wednesday, Sept.

The World Health Organization has approved the rollout of an injectable HIV preventive drug; Lenacapavir or LEN. The National ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

In the mid-1990s, my then-husband passed away from complications of HIV/AIDS. From the time he was diagnosed until he died, all of us, friends and family, but most of all, him, knew how it would end.

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...